Obesity is a complex disease and leading cause of morbidity and mortality and there are only insufficient treatment options available
New collaboration aims to develop novel peptide poly-agonists for the treatment of obesity and concomitant diseases
Gubra may receive up to EUR 240 million in upfront and success-based development and commercialization milestones plus staggered up to double-digit royalties on worldwide net sales
INGELHEIM, Germany & HØRSHOLM, Denmark -- (BUSINESS WIRE) --
Boehringer Ingelheim and Gubra announce a second collaboration and license agreement for the development of novel poly-agonist peptides to treat obesity. It will bring together Gubra’s established expertise in the design, synthesis, pharmaceutical characterization and in vivo testing of therapeutic peptides with Boehringer Ingelheim’s expertise in the research and development of innovative medicines in cardiometabolic diseases.
This second joint research and development program between Boehringer Ingelheim and Gubra builds on a successful ongoing collaboration in the obesity field, which was launched in 2017, and which has already achieved important milestones. It contributes to the growing Boehringer Ingelheim research and development stage portfolio in the obesity field.
“We look forward to expanding our productive collaboration with the Gubra team,” said Clive R. Wood, Ph.D., Corporate Senior Vice President Discovery Research at Boehringer Ingelheim. “I anticipate that these programs will help us bring much needed new treatment options for obesity patients.”
Boehringer Ingelheim has built a broad portfolio of marketed products for thromboembolic diseases, type 2 diabetes, acute stroke and myocardial infarction, hypertension and cardiovascular death risk reduction. With its extensive experience in the field and commitment to innovation, the company aims to transform the lives of people with cardiometabolic diseases.
Henrik Blou, CEO of Gubra said, “We are very pleased to enter into a second collaboration and license agreement with Boehringer Ingelheim focusing on the treatment of obesity. It is important for Gubra to find strong partners for our proprietary research programs, and our first collaboration with Boehringer Ingelheim has shown that the strengths of both companies are nicely complementary. Joining forces on this novel research program has the potential to take obesity treatment to the next level to the benefit of patients around the world.”
调查组:权健部分产品涉虚假宣传 已请专家协助
达因苏边境派出所学习贯彻党的十九届五中全会
从24岁开始学ABC 邓亚萍《我相信》亲述求学之路
韩国自动化专业企业KCC精工瞄准海外市场
吉利汽车获莱茵整车级固体颗粒物气溶胶过滤防
新时期、新中考 --广外伴你开启新梦想--
WGS 2019:世界政府峰会无疑是全球重要改变的催
铠侠将向乌克兰人民捐赠1亿日元,用于人道主
Court Denies Majority of Moto
教育现代化浪潮下 “游戏化”教育加速入场
Bentley 软件公司宣布基础设施项目利用由
湘潭市开展健康促进医院创建考评验收工作
APR获得1万亿韩元的Pre-IPO投资
嘉盛电源获颁TuV莱茵国内首张DIN 70122
湖北建华建设工程咨询有限公司为新冠战“疫”
固铂轮胎赢得两项2019 GOOD DESIGN®全球大奖
2020ITES深圳工业展完美收官,百超迪能重磅亮相
鼎和保险公司多措并举应对沙尘暴天气
新的独立研究报告显示,数据虚拟化可带来40
MSCI推出第一批数字资产指数
Forescout拓展亚太和日本业务,新设新加坡总部
滨城区四中线上升旗仪式——传承五四精神,绽
akaBot携手Soroco提升流程优化解决方案
Takeda to Divest TachoSil